Letrozole 2.5 mg
| Product Overview | |
| Generic Name | Letrozole 2.5 mg |
| Brand Name(s) | Femara, Oncolet, Feofar, Zaronil, and others |
| Form | Oral tablet |
| Strength | 2.5 mg / 30 Tab |
| Therapeutic Class | Non‑steroidal aromatase inhibitor |
| ATC Code | L02BG04 |
| Manufacturing & Regulatory | |
| Manufacturer | Novartis (Femara); multiple Indian generics (Alna Biotech, Biochem etc.) |
| Country | India |
| GMP Compliance | WHO/cGMP-compliant |
| DMF/CEP | Type II |
| COFEPRIS | Under Registration (2025) |
| Free Sale Certificate | Yes |
| Logistics & Export | |
| MOQ | Pack of 25 |
| Shelf Life | 36 months |
| Storage | 20–25 °C, protect from light; do not freeze |
| Incoterms | EXW/FOB/CIF negotiable |
| Lead Time | 7 - 10 Business Days |
| Documentation | |
| Certificate of Analysis (COA) | Supplied per batch upon supply |
| SDS | Yes—for API and finished product |
| CTD Summary | CTD from originator; generic use abbreviated formats |
Description
Indications & Usage: Adjuvant/ext adjuvant/advanced breast cancer in post‑menopausal women; off‑label for ovulation induction in PCOS
